HomeNDC LookupRxCUI directory › RxCUI 308096

Amifostine 500 MG Injection — RxCUI 308096

RxNorm drug concept · Semantic clinical drug
RxCUI 308096 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI308096
Official nameAmifostine 500 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Amifostine Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ethyol is a protector, not a cancer treatment itself. It's given right before your chemotherapy or radiation to help shield your healthy tissues — specifically your kidneys if you'...
  • Why am I being given this medication on the day of my chemotherapy or radiation — what is it actually doing for me?
  • That's a really important question, and your oncology team has thought about it carefully. Ethyol is designed to protect normal tissue more than tumor tissue, so for the approved u...
  • Will this medication interfere with my cancer treatment and make it less effective?
📖 Read our full Amifostine Injection guide →

🕸️ Concept Web — How Amifostine 500 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Amifostine 500 MG Injection RxCUI 308096

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Amifostine 4126
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ethyol 151722
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amifostine Injection 1721593
    • Amifostine Injectable Product 1151587
    • Amifostine Injection [Ethyol] 1803016
    • Ethyol Injectable Product 1803017
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Amifostine 500 MG SCDC · 1721592
  • Amifostine Injection SCDF · 1721593
  • Amifostine Injectable Product SCDG · 1151587

Brand-Name Concepts

  • Amifostine 500 MG Injection [Ethyol] SBD · 1803018
  • Amifostine 500 MG [Ethyol] SBDC · 1803015
  • Amifostine Injection [Ethyol] SBDF · 1803016
  • Ethyol Injectable Product SBDG · 1803017
  • Ethyol BN · 151722

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 308096 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
83107-0030-02 3 VIAL, SINGLE-DOSE in 1 CARTON (83107-030-02) / 10 mL in 1... Ethyol Legacy Pharma USA Inc. 2026-03-16
Observed labelers: Legacy Pharma USA Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.